Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings - 2Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 3Step by step instructions to Protect Your Retirement with Senior Protection.
- 4Find the Captivating Professional flowerbeds of the US
- 5A Concise History Of The Entertainment world
- Bomb blast in packed Nigerian mosque kills five
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- 74 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen
- 'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- Which Kind of Pet Makes the Incomparable Buddy?
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
- Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- Archaeologists uncover details about the Hjortspring boat's origins
- 5 Cell phones of the Year
